Form 4: Medtronic EVP & CFO Pieton Thierry Reports Changes in Beneficial Ownership

Medtronic's EVP & CFO, Pieton Thierry, reports acquisition of restricted stock units and stock options, along with performance share units.

Summary

• Thierry Pieton, EVP & Chief Financial Officer of Medtronic, filed a Form 4 detailing changes in beneficial ownership.
• On March 3, 2025, Pieton acquired 4,242 ordinary shares at $94.3 each, and an additional 26,512 restricted stock units that vest annually.
• Pieton also acquired 10,605 performance share units (PSUs) that vest on April 30, 2027, with the number of shares issued depending on performance metrics.
• Additionally, Pieton acquired 29,574 stock options exercisable in four annual installments starting one year from the grant date, expiring on March 3, 2035.
• Following these transactions, Pieton directly owns 30,754 ordinary shares and 29,574 stock options.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive. The filing reflects standard executive compensation practices and insider confidence, but doesn't contain any groundbreaking news.

Positives

• The acquisition of shares and stock options by a key executive signals confidence in the company's future performance.
• The vesting schedule of the restricted stock units and stock options incentivizes long-term commitment from the executive.
• The performance-based vesting of the PSUs aligns executive compensation with company performance.

Future Outlook

The document does not contain explicit forward-looking statements, but the vesting schedules of the equity awards suggest a focus on long-term performance.

Industry Context

Executive compensation through equity grants is a common practice in the medical device industry to align management interests with shareholder value. Medtronic's approach appears consistent with this trend.

Comparison to Industry Standards

• Medtronic's executive compensation practices, including the use of restricted stock units, performance share units, and stock options, are generally in line with those of its peers in the medical device industry, such as Johnson & Johnson, Abbott Laboratories, and Stryker.
• These companies often use a mix of equity-based compensation to incentivize executives and align their interests with long-term shareholder value creation.
• The specific vesting schedules and performance metrics associated with these awards can vary, but the overall structure is similar.

Stakeholder Impact

• The equity grants incentivize the executive to drive long-term value for shareholders.
• Employees may view the executive's stock ownership as a positive sign of commitment to the company's success.

Key Dates